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The next controversy in genetic testing:
clinical data as trade secrets?
Robert Cook-Deegan*,1,2, John M Conley3,4, James P Evans5 and Daniel Vorhaus4
Sole-source business models for genetic testing can create private databases containing information vital to interpreting the
clinical significance of human genetic variations. But incomplete access to those databases threatens to impede the clinical
interpretation of genomic medicine. National health systems and insurers, regulators, researchers, providers and patients all
have a strong interest in ensuring broad access to information about the clinical significance of variants discovered through
genetic testing. They can create incentives for sharing data and interpretive algorithms in several ways, including: promoting
voluntary sharing; requiring laboratories to share as a condition of payment for or regulatory approval of laboratory services;
establishing – and compelling participation in – resources that capture the information needed to interpret the data
independent of company policies; and paying for sharing and interpretation in addition to paying for the test itself.
US policies have failed to address the data-sharing issue. The entry of new and established firms into the European
genetic testing market presents an opportunity to correct this failure.
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BACKGROUND
Interpreting the clinical significance of genomic information depends
on broad access to DNA sequence variants and clinical information
about those tested. Some proprietary genetic test providers have
developed privately controlled databases containing information
essential to interpreting the results of their tests. This is exemplified
by BRCA1/2 testing by Myriad Genetics (Salt Lake City, UT, USA) in
the United States.
As the provider of BRACAnalysis, the sole BRCA1/2 diagnostic test
commercially available in the United States and one of the most
commercially successful genetic tests worldwide, Myriad Genetics
serves as an excellent case study of the importance of collecting
clinical data and the implications of keeping those data private.
Myriad Genetics has enjoyed market success with BRACAnalysis –
Myriad notes that nearly one million patients have had BRCA testing,
and it has payment agreements with 2500 insurers or payers.1 Its
status as the sole commercial provider of BRCA testing in the United
States is a consequence of its exclusive US patent rights. In 1994,
scientists, some of whom were affiliated with Myriad, discovered
BRCA1, which when mutated results in pronounced predisposition
to breast, ovarian and certain other cancers.2–4 Myriad-associated
scientists co-discovered the BRCA2 gene the following year. Myriad
patented its discoveries and acquired BRCA patent rights from others.
It became the sole commercial testing service for BRCA1/2 in the
United States by asserting its patents and clearing the market of US
competitors,5 generating over $105 million from its BRACAnalysis
test in the second quarter for calendar year 2012.6
Myriad has several competitive advantages based on its long
experience in BRCA testing. It runs a highly efficient laboratory, has
developed a network of health professionals who use its services, has
secured agreements with hundreds of payers, has brand recognition
based in part on direct-to-consumer advertising, and has a trained
sales force. Although those advantages should abide any change in
patent status or data access policies, Myriad’s entry into Europe,
projected for later this year,6 presents an opportunity to implement
policies on access to BRCA mutation data that can set a salutary
precedent not only for BRCA but for genetic testing in general,
including whole-genome analysis.7,8
INTERPRETING VARIANTS OF UNKNOWN SIGNIFICANCE
Most patients who get BRCA testing have results that can be
interpreted in a relatively straightforward manner – either no
variations from ‘wild type’, harmless sequence variations or a clearly
deleterious mutation. Such results are valuable to those tested and to
their providers, influencing decisions about treatment options,
including prophylactic surgery or close monitoring and medical
management. Mutations that clearly disrupt protein function
(e.g., through a small insertion or deletion that results in a frame
shift) are generally obvious upon inspection.
In a significant minority of tests, however, sequence differences
from wild type are difficult to interpret. These are ‘variants of
unknown significance’ (VUS). Missense mutations that substitute
one amino acid for another or changes near intron–exon boundaries
can be particularly difficult to interpret. Myriad claims that the
fraction of cases resulting in a VUS is 3% in its hands, and 20% for
most European BRCA-testing services.1 This discrepancy is at least in
part due to Myriad having sole possession of the information needed
to interpret VUS results. Myriad has obtained this exclusivity by using
its status as the sole BRCA1/2 test provider to develop, at its own cost,
an extensive database that relates variants of uncertain significance to
phenotype, details their frequency in various populations and
includes genetic studies on patient families. Thus, Myriad’s
proprietary database that contains information about variants,
which is not found in public databases, is probably the major
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factor in explaining the company’s ability to interpret VUS results
more successfully than others.
To its credit and the benefit of patients, Myriad has used its
database to reduce the frequency with which it reports a VUS. When
Myriad finds a new VUS – or one previously identified but whose
clinical significance is not yet understood – it offers free testing to the
patient’s family members (something that not all genetic testing
laboratories do) in an effort to help determine the variant’s
significance. Myriad encourages the person with the VUS to contact
others in their family, providing a model letter that patients
can send their relatives. Myriad collects data regarding the clinical
outcome associated with that VUS, and a VUS may ultimately be
reclassified as deleterious or neutral as more is learned; conversely,
deleterious or neutral mutations are occasionally reclassified as VUSs.
Myriad has access to public databases in interpreting mutations,
but outsiders do not have access to Myriad’s database. This
asymmetry has clinical impact: a woman might be able to receive
BRCA testing from another laboratory in Malawi or Malta, where
Myriad’s BRCA patent rights are not in force and testing is perfectly
legal, but that laboratory will have no access to Myriad’s data and will
thus be unable to interpret many VUS results. Geographic inequities
are common in the market for medical products and services. But the
fact that the inequity is based on the availability of basic scientific and
medical information, rather than of a drug or product, changes the
policy context, prompting a debate about keeping clinically relevant
data proprietary when that secrecy makes independent verification of
its medical significance impossible.
In an environment in which new technologies, including whole-
genome and whole-exome sequencing, are already beginning to
change clinical practices in genetic testing,9–11 a proprietary
database gives Myriad indefinite exclusivity independent of patent
protection. Even if Myriad’s patents are invalidated (for a summary of
the ongoing court challenge, see Supplementary materials), or new
alternative testing technologies do not infringe them, until the data
and interpretive algorithms are re-created in publicly accessible
form, competing services will be able to manage VUS results in
only two ways: by having samples analyzed at Myriad, where it is
interpreted in light of Myriad’s proprietary database, or by rendering
inadequate interpretations based upon incomplete public
data and algorithms. The former perpetuates Myriad’s exclusivity
even after the expiration of its patent rights, while the latter is
unacceptable from a clinical perspective. In either case, current
practice permits the privatization of valuable clinical data obtained
from patients.
DATA-SHARING PRACTICES
Myriad contributed data to public databases until late 2004, but since
then its contributions have essentially stopped. Its last major deposit of
data to the Breast Cancer Information Core (BIC, the largest database
for BRCA mutations, maintained by the National Human Genome
Research Institute) was in November 2004. Myriad officials explained
to one of us (RC-D) that the decision not to share data was initially
because of difficulties in matching data formats, but that after 2005, the
company adopted a deliberate policy of retaining data as a trade secret.
Myriad has published some articles on VUS data since November
2004 when its public data-sharing stopped. Investigators with access
to the Myriad database through 2006, did the most extensive analysis
of VUS, reporting 18 deleterious and 100 neutral variants out of 1433
variants they studied.9 Those 118 sequence variants of known
significance are now in the public literature. More than 1200
variants are mentioned in that publication, but the sequences are
not listed, and the interpretive algorithms are not specified in detail or
deposited where others can use them to interpret the data. Thus,
Myriad’s general approach to ‘calling’ VUS results is described, but
neither analytic algorithms nor underlying sequence data are
available.9–13 This contrasts with recommendations of the National
Academies in two reports that call for depositing data and methods
sufficient for replication and interpretation.14,15
Myriad’s exclusive US testing rights and its pursuit of cases of VUS
have enabled it to accumulate data that confer a proprietary advantage
in BRCA test interpretation worldwide. Some will surely point to this
as a legitimate benefit bestowed by the patent system, part of Myriad’s
just reward for innovating. Patents gave Myriad exclusive access to
those seeking genetic testing, which enabled Myriad, in turn, to
produce a valuable database. Others, however, are likely to consider the
withholding of unpatented patient data to hinder rather than ‘to
promote the progress of science and useful arts,’ the Constitutional
mandate upon which the US patent system is founded. Arguments
that focus on rewarding innovation, moreover, must also take into
account that much of the work that led to the isolation of BRCA1/2
was done with public or nonprofit funding. The practical effect of
retaining such data as a trade secret is to extend Myriad’s testing
monopoly beyond the life of the patents on which it was founded.
Whole genome analysis stands poised to have a major impact on
medical care if it can be harnessed appropriately. But the biggest
challenge to its implementation is properly interpreting the variants
found upon analyzing any individual’s genome. As whole-genome
and whole-exome sequencing become commonplace, the rate of truly
novel mutations will eventually decline. For the foreseeable future,
however, each individual whose genome is sequenced will have vast
numbers of variants of uncertain clinical significance.
Comprehensive databases such as The Human Gene Mutation
Database in Cardiff, MutaDATABASE, the Human Variome Project
database, the Leiden Open Variation Database, and other public
databases will be essential resources for tracking and interpreting VUS
data. Those databases depend, however, on sharing sufficient infor-
mation to make genotype–phenotype correlations. Myriad, Preven-
tion Genetics and Medical Neurogenetics are the only three
laboratories not agreeing to contribute data on human genetic
variants to MutaDATABASE, in contrast to over 100 services that
have agreed to contribute mutation data (including GeneDx, Quest/
Athena, LabCorp and other large commercial testing services).16 The
Evidence-based Network for the Interpretation of Mutant Germline
Alleles (ENIGMA) was funded as a US National Institutes of Health
challenge grant in 2009 to focus on interpreting VUS results from
BRCA genes in the public domain.17–19 It draws from databases and
colleagues around the world to apply bioinformatic and laboratory
biological methods to improve VUS interpretation. ENIGMA has
access to data in Myriad’s database through 2006, but not from the
past 5 years.
The objective of these databases and research consortia is to
accumulate data and to refine interpretive methods to create a
publicly available foundation for improving clinical interpretation
of genetic testing. As these public resources accumulate data, the value
of proprietary databases will eventually erode, but in the meantime
clinicians will be ordering and health plans will be paying for many
genetic results that cannot be accurately interpreted based on publicly
available information.
POLICY OPTIONS
To deal with this conundrum, one set of policy options involves
leveraging the influence of scientific journals and organizations by
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applying existing disclosure standards. Medical journals and scholars
have legitimate claims on data and methods for clinical interpretation
of mutations. The 2003 National Academies report on publication of
genomic data recommended that ‘authors should include in their
publications the data, algorithms or other information that is central
or integral to the publication – that is, whatever is necessary to
support the major claims of the paper and would enable one skilled in
the art to verify or replicate the claims’.15 The Uniform Requirements
for Submission of Manuscripts to Medical Journals mandates that
authors ‘identify the methodsy and procedures in sufficient detail to
allow others to reproduce the results’.20 The importance of
replicability and objective, independent access to data and
algorithms was reiterated in the March 2012 report from the
Institute of Medicine (IOM), which recommended that ‘data and
metadata used for development of the candidate omics-based test
should be made available in an independently managed database’.14
IOM also recommended that computer code and computational
methods be fully shared, either through a public database, publication
or in the process of regulatory review. These criteria imply a norm of
access to data and analytical methods sufficient to make clinical
inferences about VUS results.
Leveraging publication standards holds promise but also has
limitations. Some journals already require public deposit of data
sufficient to independently interpret reported mutations. But as noted
above, Myriad’s publications gave the sequences of only 118 of more
than 1400 mutations studied, and did not include the interpretive
algorithms. Publication guidelines, moreover, apply only when the
benefits of publication are sought; they obviously do not apply to
unpublished VUS data.
As a related option, databases listing mutations or availability of
genetic tests (e.g., the NIH’s nascent Genetic Testing Registry) could
mandate test providers share sequence data and interpretive algo-
rithms as a condition of listing their tests. In addition, physicians
receiving results, or the organizations that collectively represent them,
could also demand access to underlying data and algorithms. For
example, standards for reporting such results could be established by
the European Society for Human Genetics or international scientific
and medical organizations.
Another set of options would rely on the power of payers and
regulators. Payers currently reimburse bundled genetic tests and
interpretive services. In cases when interpretation cannot be inde-
pendently verified, payers would be on firm ground to request – or
demand – the evidence underlying the clinical determinations.
National health systems, insurers and regulators have several policy
tools at their disposal to ensure independent validation of clinical
inferences about genomic variants. First, they could ask testing firms
to voluntarily adopt policies to share mutation data publicly. Second,
payers could refuse payment unless clinically relevant data are shared
and subject to independent verification for both accuracy and validity
of interpretation. This option further bifurcates into (1) disclosure
only to payers or providers, or (2) full public disclosure. That is, if
payers mandated data access, disclosure could be limited to regulatory
authorities or to those making coverage and payment decisions.
Alternatively, payers could require – as a condition of payment –
deposit of data and interpretive algorithms into public databases to
enable open and independent evaluation, building on the IOM
recommendations. Similarly, national authorities that regulate
genomic tests could mandate public disclosure as a condition of
pre-market approval. Third, national and international institutions
could fund research to re-create the data in proprietary databases by
ensuring that results of genetic analysis get incorporated into large
databases. Such an option, although redundant and thus expensive,
might be accomplished through electronic health records that include
genomic as well as clinical data, or by building out from consortia
such as ENIGMA that have been established for just this purpose – to
collect data and develop analytical methods as a public research and
clinical resource. Fourth, national health systems could craft payment
policies to create incentives for disclosure of data needed to interpret
genetic tests – for example, establishing payment codes for public
deposit and interpretation of genomic data, in addition to performing
the test itself – thus rewarding firms that disclose valuable data.
CONCLUSION
Current practices of proprietary databases may hinder interpretation
of genomic data and impede the advance of personalized medicine.
Policies to reward or require data sharing can prevent some foresee-
able problems caused by limited access to proprietary data about
the clinical significance of genetic variations. Myriad Genetics, for
example, has leveraged its BRCA patents to become the dominant
BRCA testing service and, in turn, to create a valuable database.
Myriad clearly sees its proprietary database as a source of competitive
advantage, one that will persist after its underlying patents expire or
are invalidated in court. Because of its public profile and explicit,
data-based business plan, Myriad’s entry into Europe will force policy
choices into stark relief, just as the reduced cost of full-genome
analysis brings a worldwide deluge of genomic data. Payers in the
United States did not foresee the problems of incomplete access to
data, and did not put in place policies to ensure independent
verification of clinical predictions. Hundreds of agreements have
been signed between genetic testing firms and US payers that have
apparently not required disclosure of the underlying data, which is
ultimately derived from – and would benefit – patients seeking
optimal treatment. Payers and regulators in Europe, South America,
Asia and other markets need not be so passive. With the entry of
Myriad into Europe in 2012, those making policy decisions about
regulation, coverage and reimbursement of genetic tests in Europe can
ensure that the data necessary to interpret the clinical significance of
genetic variations are made public, where they can be subjected to
scientific scrutiny and be available to benefit patients and health
professionals around the world.
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